ReviewJournal of neuro-oncology2023
Updates on the WHO diagnosis of IDH-mutant glioma.
Review in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Article
- Integrated Transcriptomic Analysis Reveals Coordinated Gliovascular Remodeling Across Diffuse Glioma Grades.Cancers · 2026Article
- Clinicopathological Implications of IDH1 Mutation and Ki-67 Expression Across WHO Grades of Gliomas: Insights from a Prospective Observational Study.Iranian journal of pathology · 2026Article
- Diagnostic Pitfalls of Oligodendroglioma-like Morphology: Integrated Reappraisal of 23 Non-Oligodendroglial Central Nervous System Tumors.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Integrated transcriptomic analysis reveals KRAS-associated gene activation and epigenetic regulation in mutant IDH1 glioma.Genes & genomics · 2026Article
- Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Asia-Pacific journal of clinical oncology · 2026Review
- Identifying clinically relevant cell state interactions in the tumor microenvironment of IDH-mutant gliomas using CSI-TME.Molecular systems biology · 2026Article
- Preoperative assessment of IDH status in adult glioma by integratedEJNMMI research · 2026Article
- Article
- Characteristics of [European journal of nuclear medicine and molecular imaging · 2026Article
- Spatial heterogeneity of malignant molecular markers in glioma revealed by stereotactic biopsy.Discover oncology · 2026Article
- IDH Mutation Assessment in Gliomas from Anatomical MRI Using Deep Learning: A Comparative Analysis of Centralized and Federated Learning Frameworks.Diagnostics (Basel, Switzerland) · 2026Article
- Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Generating crossmodal gene expression from cancer histopathology improves multimodal AI predictions.Nature communications · 2025Article
- Prognostic Value of MCM3AP-AS1 in Glioma and its Regulatory Effect on Tumor Progression.Neurochemical research · 2025Article
- Design of mismatch closure for enhanced specificity in DNA strand displacement reactions.Nucleic acids research · 2025Article
- Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005-2020).Brain sciences · 2025Article
- Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?Diagnostics (Basel, Switzerland) · 2025Article
- Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors.Neuro-oncology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe WHO classification of Tumors of the Central Nervous System represents the international standard classification for brain tumors. In 2021 the 5th edition (WHO CNS5) was published, and this review summarizes the changes regarding IDH-mutant gliomas and discusses unsolved issues and future perspectives.
methodsThis review is based on the 5th edition of the WHO Blue Book of CNS tumors (WHO CNS5) and relevant related papers.
resultsMajor changes include taxonomy and nomenclature of IDH-mutant gliomas. Essential and desirable criteria for classification were established considering technical developments. For the first time molecular features are not only relevant for the classification of IDH-mutant gliomas but may impact grading as well.
conclusionWHO CNS5 classification moves forward towards a classification which is founded on tumor biology and serves clinical needs. The rapidly increasing knowledge on the molecular landscape of IDH-mutant gliomas is expected to further refine classification and grading in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.